West Pharmaceutical Services holds the cleaner structural position, with the lead spread across profitability and growth. Siegfried still leads on valuation and stability, which keeps the comparison from looking entirely one-sided. On the market side, West Pharmaceutical Services is in better shape — its trend is intact while Siegfried's trend has broken down. That puts structure and market broadly in agreement — West Pharmaceutical Services's lead looks more confirmed than conflicted.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (SFZN.SW: STOXX 600, WST: Russell 1000).
The lead is spread across profitability and growth, rather than sitting in one isolated gap. The overall score gap is 10 points in favour of West Pharmaceutical Services, Inc..
This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.
A solid similarity means the pair shares a clearly comparable long-term financial profile, even if individual dimensions still differ.
The clearest structural overlap shows up in revenue growth trajectory and investment intensity.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
West Pharmaceutical Services, Inc. is cheaper, but Siegfried Holding AG is still stronger.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where SFZN.SW and WST each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 6.4-point ROIC advantage.
Absolute pricing still looks more supportive for Siegfried, with a forward P/E that is 14.3 turns lower there.
The lead is built on both profitability and growth — though valuation still provides a counterweight.
Break down the SFZN.SW vs WST comparison across all dimensions with the full interactive tool.
Explore how SFZN.SW and WST each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.